AVEO Pharmaceuticals Number of Employees 2010-2022 | AVEO

AVEO Pharmaceuticals number of employees from 2010 to 2022. Number of employees can be defined as a measure of financial performance calculated as operating cash flow minus capital expenditures, expressed on a per share basis
AVEO Pharmaceuticals Annual Number of Employees
2021 115
2020 49
2019 19
2018 17
2017 19
2016 20
2015 19
2014 57
2013 71
2012 219
2011 220
2010 147
2009
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.211B $0.042B
AVEO Pharmaceuticals, Inc. is a biopharmaceutical company engaged in discovering, developing and commercializing novel cancer therapeutics. Its product candidates are targeted against important mechanisms known or believed to be involved in cancer. Tivozanib, the Company's lead product candidate, is a highly potent and selective oral inhibitor of the vascular endothelial growth factor, or VEGF, receptors 1, 2 and 3. In addition to tivozanib, AVEO Pharmaceuticals has a pipeline of monoclonal antibodies derived from Human Response Platform (HRP), a novel method of building preclinical models of human cancer, which are intended to more accurately represent cancer biology in patients. AV-299 is the Company's next product candidate which is an antibody that binds to hepatocyte growth factor, or HGF, thereby blocking its function. AVEO Pharmaceuticals, Inc. is based in Cambridge, Massachusetts.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $166.663B 10.14
Bio-Rad Laboratories (BIO.B) United States $14.121B 30.63
QIAGEN (QGEN) Netherlands $10.600B 16.73
Biohaven Pharmaceutical Holding (BHVN) United States $10.272B 0.00
Ginkgo Bioworks Holdings (DNA) United States $4.442B 0.00
Arcus Biosciences (RCUS) United States $1.751B 44.38
Emergent Biosolutions (EBS) United States $1.534B 6.57
Myovant Sciences (MYOV) United Kingdom $1.224B 0.00
Zymeworks (ZYME) Canada $0.317B 0.00
Gelesis Holdings (GLS) United States $0.111B 0.00
Ambrx Biopharma (AMAM) United States $0.100B 0.00
Enzo Biochem (ENZ) United States $0.097B 0.00
SQZ Biotechnologies (SQZ) United States $0.089B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00